Pfizer beat third-quarter expectations and raised its 2021 forecast again even as sales of its top product, the COVID-19 vaccine Comirnaty, slipped in the U.S. Soaring international sales of the preventive shots helped pushed total Comirnaty revenue close to $13 billion in the quarter, and the drugmaker said Tuesday that it now expects to book about $36 billion in sales from the vaccine this year
Related posts
-
Metra could borrow from feds to fix 100-year-old bridges
Metra may leverage federal loans to rebuild aged bridges, aiming to ensure reliable service. -
Des Plaines to buy — and raze — two buildings on Lee Street
Des Plaines is spending $420,000 for two vacant buildings on Lee Street, with an eye toward... -
District 203 school board clash highlights ongoing tensions
Naperville Unit District 203 school board members clashed Tuesday over a routine vote to pay bills,...